# A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

> **NCT07050368** · PHASE1 · COMPLETED · sponsor: **MycoMedica Life Sciences PBC** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07050368
- **Lead sponsor:** MycoMedica Life Sciences PBC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-28
- **Primary completion:** 2026-01-13
- **Final completion:** 2026-01-13
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07050368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07050368, "A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07050368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*